Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 140 of the 141 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The aim was to formulate practice guidelines for the diagnosis and treatment of hyperprolactinemia. PARTICIPANTS: The Task Force consisted of Endocrine Society-appointed experts, a methodologist, and a medical writer. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society, The European Society of Endocrinology, and The Pituitary Society reviewed and commented on preliminary drafts of these guidelines. CONCLUSIONS: Practice guidelines are presented for diagnosis and treatment of patients with elevated prolactin levels. These include evidence-based approaches to assessing the cause of hyperprolactinemia, treating drug-induced hyperprolactinemia, and managing prolactinomas in nonpregnant and pregnant subjects. Indications and side effects of therapeutic agents for treating prolactinomas are also presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have reported that 44-62% of cases experience a reversal of hypogonadism, usually within 6 months after starting treatment (225,226).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [226]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Persistently elevated prolactin levels can indicate the presence of pituitary tumors, such as prolactinomas”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“development and implementation of evidence-based guidelines (1).”
Fernandez, A., Karavitaki, N., & Wass, J. A. H. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03667.x · Cited by 1,115
Self-citationHigh Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liège, Belgium
Daly, A. F., Rixhon, M., Adam, C., Dempegioti, A., Tichomirowa, M. A., & Beckers, A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1668 · Cited by 1,025
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2847 · Cited by 965
Self-citationValvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
Casanueva, F. F., Molitch, M. E., Schlechte, J. A., Abs, R., Bonert, V., Bronstein, M. D., Brue, T., Cappabianca, P., Colao, A., Fahlbusch, R., et al. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02562.x · Cited by 829
Self-citationAdvances in the Treatment of Prolactinomas
Gillam, M. P., Molitch, M. E., Lombardi, G., & Colao, A. (2006) · Endocrine Reviews · doi:10.1210/er.2005-9998 · Cited by 824
A Radioimmunoassay for Human Prolactin
Hwang, P., Guyda, H., & Friesen, H. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.8.1902 · Cited by 752 · cited 2×
“1970 permitted development of RIAs (4, 5), which en-”
Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 718
A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea
Webster, J., Piscitelli, G., Polli, A., Ferrari, C. I., Ismail, I., & Scanlon, M. F. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311403 · Cited by 699
Cited by
Items 901–1,000 of 1,001
A Current Approach to Hyperprolactinemia
Lau, C. S., & Aw, T. C. (2019) · International Archives of Endocrinology Clinical Research · doi:10.23937/2572-407x.1510018 · Cited by 5
Management of pituitary tumors in pregnancy
Glezer, A., Jallad, R. S., Machado, M. C., & Bronstein, M. D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819949-7.00049-4 · Cited by 6
Mutlu, Ü., Çaklılı, Ö. T., Barbüroğlu, M., & Yarman, S. (2022) · HORMONES · doi:10.1007/s42000-022-00401-x · Cited by 7
“The prolactinoma was diagnosed with high PRL levels (> 150 ng/ml) and the presence of a pituitary adenoma on MRI [21].”
BackgroundChanson, P., & Maiter, D. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99899-4.00011-1 · Cited by 5
Demir, D., Demir, A. N., Sulu, C., Zulfaliyeva, G., Çetintaş, S. C., Özkaya, H. M., Kadıoğlu, P., Gazioğlu, N., & Tanrıöver, N. (2023) · World Neurosurgery · doi:10.1016/j.wneu.2023.04.089 · Cited by 6
Mazar‐Atabaki, A., Mohamadzadeh, O., Sadrehosseini, S. M., Tabari, A., & Zeinalizadeh, M. (2023) · Clinical Case Reports · doi:10.1002/ccr3.7808 · Cited by 5
Follow-Up Study of a Pharmacovigilance Signal
McCarren, M., Qiu, H., Ziyadeh, N. J., Jiang, R., Wang, Y., & McAfee, A. T. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318271069d · Cited by 5
The higher incidence of autoimmune thyroid disease in prolactinomas than in somatotrophinomas
Doğanşen, S. Ç., Selçukbiricik, Ö. S., Bilir, B. E., & Yarman, S. (2016) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2016.04.004 · Cited by 6
Three Novel MEN1 Variants in AIP-Negative Familial Isolated Pituitary Adenoma Patients
Yarman, S., Tuncer, F. N., & Serbest, E. (2019) · Pathobiology · doi:10.1159/000495252 · Cited by 5
Maiter, D. M. (2019) · Contemporary Endocrinology · doi:10.1007/978-3-030-11836-5_11 · Cited by 5
Modern approaches to diagnostics of hyperandrogenism distributed forms in reproductive aged women
Бурка, О. А., & Tutchenko, T. М. (2019) · Reproductive Endocrinology · doi:10.18370/2309-4117.2019.46.39-45 · Cited by 6
Nass, R. M., Helm, K. D., & Evans, W. S. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2758-2.00021-4 · Cited by 6
Menstrual disorders in chronic kidney disease: causes and management
Garg, S. S., & Ramalakshmi, D. S. (2020) · International Journal of Clinical Obstetrics and Gynaecology · doi:10.33545/gynae.2020.v4.i2f.549 · Cited by 5
“Bromocriptine or cabergoline administration may be effective in treatment of patients presenting with amenorrhea or galactorrhoea ([19]).”
BackgroundChronic Lactiferous Fistula: A Case Report
Shamsudin, S., Norie, A. K., & Haida, H. (2017) · IIUM Medical Journal Malaysia · doi:10.31436/imjm.v16i1.370 · Cited by 5
An Update on Immune Checkpoint Inhibitor-related Hypophysitis
Mortensen, M. J., Oatman, O. J., Azadi, A., Fonkem, E., & Yuen, K. C. J. (2020) · US Endocrinology · doi:10.17925/use.2020.16.2.117 · Cited by 5
Nawroth, F. (2019) · Der Gynäkologe · doi:10.1007/s00129-019-4453-3 · Cited by 5
Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline
Ludlam, W. H. (2011) · Yearbook of Endocrinology · doi:10.1016/j.yend.2011.06.062 · Cited by 5
Is chronic nipple piercing associated with hyperprolactinemia?
Sun, G. E. C., Pantalone, K. M., Gupta, M. K., Kennedy, L., Nasr, C. E., Constantiner, M., Hamrahian, A. H., & Hatipoğlu, B. (2012) · Pituitary · doi:10.1007/s11102-012-0431-7 · Cited by 5
Adénome à prolactine : du désir de grossesse à l’accouchement
Fatfouta, I., Delotte, J., Mialon, O., Isnard, V., & Bongain, A. (2012) · Journal de gynécologie, obstétrique et biologie de la reproduction. Supplément/Journal de gynécologie obstétrique et biologie de la reproduction · doi:10.1016/j.jgyn.2012.08.001 · Cited by 5
“Elle entraîne une altération du rétrocontrôle positif de l’estradiol sur la sécrétion de gonadotrophine ainsi qu’une inhibition de production de progestérone par les cellules de la granulosa [3].”
BackgroundInfluentialGiant macroprolactinoma and pregnancy
Saraiva, J. C., Gomes, L., Paiva, S., Ruas, L., & Carvalheiro, M. C. (2013) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302013000700010 · Cited by 5
“The latest guidelines recommend reinstitution of therapy with bromocriptine (5).”
BackgroundInfluentialDopamine agonist withdrawal in hyperprolactinemia: when and how
Salvatori, R. (2017) · Endocrine · doi:10.1007/s12020-017-1469-0 · Cited by 5
Effects of cabergoline therapy on serum IGF-1 concentrations in prolactinoma patients
Iglesias, P., Villabona, C. M., & Díez, J. J. (2019) · Pituitary · doi:10.1007/s11102-019-01011-4 · Cited by 5
Zacharia, S. S., Thomas, R., Johnson, J. T., Kapoor, N., Ramanathan, S., Asha, H. S., Cherian, K. E., & Paul, T. V. (2024) · Pituitary · doi:10.1007/s11102-024-01433-9 · Cited by 5
Endocrine paraneoplastic syndromes in lung cancer: A call for clinical vigilance (Review)
Koloutsou, M. E., Soura, M., Andreikos, D., Spandidos, D. A., Yavropoulou, M. P., & Georgakopoulou, V. (2025) · Molecular and Clinical Oncology · doi:10.3892/mco.2025.2831 · Cited by 7
Bioletto, F., Bogeat, C., Barat, M., Benanteur, N., Guignat, L., Hage, M. P., Garcia, C., Calugaru, V., Jacob, J., Arrondeau, J., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf136 · Cited by 4
Wang, Y., Guan, X., Ma, S., Zhang, Y., Yang, J., Liu, Y., Sun, Y., Ma, L., Li, D., Tang, Y., et al. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-02189-7 · Cited by 4
“Pituitary neuroendocrine tumor (PitNET), also known as pituitary adenoma, accounts for 10 – 20% of all intracranial tumors, with a reported prevalence of approximately 70 – 100 cases per 100,000 individuals 1,2 .”
Damianse, S. D. S. P., Nascimento, G. C., Rocha, V. C. D. C., Nascimento, A. G., Gaido, N. C., Azulay, R. S. D. S., dos Santos, W. C., Rodrigues, V. P., Quidute, A. R. P., Magalhães, M., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.02.010 · Cited by 4
Acquired hypoprolactinemia in men, possible phenotype
Corona, G., Rastrelli, G., Sparano, C., Vignozzi, L., & Maggi, M. (2024) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-024-09895-9 · Cited by 7
Liu, J., Xue, L., Fang, X., Zheng, C., Zeng, F., Liu, Y., Zhang, J., & Chen, H. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177551 · Cited by 5
Endoscopic endonasal transcavernous surgery for a contemporary series of 59 prolactinomas
Nakase, T. C., Ljubimov, V. A., Chang, J., Vogel, H. S., Vigo, V., Katznelson, L. J., & Fernandez-Miranda, J. C. (2025) · Pituitary · doi:10.1007/s11102-025-01545-w · Cited by 4
“Women often present with or neurological emergencies such as pituitary apoplexy or rapidly progressive vision loss [11, 12].”
Christoforidis, A., Tsakalides, C., Anastasiou, A. L., Pavlaki, A., & Dimitriadou, M. (2013) · PubMed · Cited by 4
Sirilert, S., Traisrisilp, K., Pantasri, T., & Tongsong, T. (2019) · Clinical Case Reports · doi:10.1002/ccr3.2244 · Cited by 4
Huang, J., Chen, M., Chen, C., Lin, X., Jiang, D., Zhang, Y., Wang, L., Zhuo, C., Tian, H., & Du, C. (2019) · Psychiatry and Clinical Psychopharmacology · doi:10.1080/24750573.2019.1662629 · Cited by 4
Thyroid, Adrenal, PRL Impairments and Ovarian Function
Tomatis, V., Battipaglia, C., & Genazzani, A. D. (2021) · Endocrines · doi:10.3390/endocrines2030021 · Cited by 8
“Such effects may impair ovulation, creating a predisposition to infertility, decreasing libido, and frequently inducing galactorrhea [47,48].”
BackgroundNawroth, F. (2015) · Der Gynäkologe · doi:10.1007/s00129-014-3509-7 · Cited by 4
Arnold, L. M., DeWitt, J. C., & Thomas, A. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00028-9 · Cited by 6
Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma
Hayes, A. G., Shirazi, M. G., Thiyagarajah, A., Torpy, D. J., & Sousa, S. M. C. D. (2022) · Endocrine Oncology · doi:10.1530/eo-22-0086 · Cited by 4
Identification of the enhancer RNAs related to tumorgenesis of pituitary neuroendocrine tumors
Wang, L., Wei, C., Wang, Y., Huang, N., Zhang, T., Dai, Y., Li, X., Lin, S., & Wu, Z. B. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1149997 · Cited by 4
Evaluation of pulmonary side effects in prolactinoma patients treated with cabergoline
Soyluk, Ö., Bingöl, Z., Doğanşen, S. Ç., Kurtulmuş, N., Tanrıkulu, S., & Yarman, S. (2023) · Endokrynologia Polska · doi:10.5603/ep.a2023.0045 · Cited by 4
Sakata, K., Hashimoto, A., Takeshige, N., Orito, K., Nagayama, A., Ashida, K., Nomura, M., & Morioka, M. (2024) · Endocrine · doi:10.1007/s12020-024-03835-y · Cited by 6
Hyperprolactinemia in women: treatment
Benetti‐Pinto, C. L., Nácul, A. P., Silva, A. C. J. D. S. R. E., Maciel, G. A. R., Nogueira, V. D. S. N., Elias, P. C. L., Martins, M. R. A., Kasuki, L., Garmes, H. M., & Glezer, A. (2024) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.61622/rbgo/2024fps05 · Cited by 4
“(40) A recent review of the literature showed that patients with antipsychotic-induced HPRL may benefit from replacement or association with aripiprazole, an antipsychotic that does not cause HPRL. (40)”
BackgroundInfluentialVilar, L., Vilar, C. F., Lyra, R., de Albuquerque, L. L., Garrido, A. C. T., Gadelha, P. S., Diniz, E. T., Almeida, M., Cordeiro, L. H. D. O., de Carvalho, É. H., et al. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2023-0391 · Cited by 4
Temizkan, O., Temizkan, Ş., Aşıcıoğlu, O., Aydın, K., & Kucur, S. K. (2014) · Gynecological Endocrinology · doi:10.3109/09513590.2014.958989 · Cited by 4
“The upper limit of the PRL was accepted 25 ng/ml [18].”
BackgroundChanges in circadian rhythm of prolactin in short children are dependent on growth hormone secretion
Stawerska, R., Smyczyńska, J., Hilczer, M., & Lewiñski, A. (2014) · Annals of Agricultural and Environmental Medicine · doi:10.5604/1232-1966.1108622 · Cited by 5
Nanba, K., Usui, T., Nakakuki, T., & Shimatsu, A. (2013) · BMJ Case Reports · doi:10.1136/bcr-2013-009986 · Cited by 4
Margari, N., Pollock, J., & Stojanovic, N. D. (2016) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-15-0103 · Cited by 4
Adénomes hypophysaires agressifs et résistants au traitement
Cuny, T., & Chanson, P. (2013) · Annales d Endocrinologie · doi:10.1016/s0003-4266(13)70016-7 · Cited by 4
Microarray data analysis reveals differentially expressed genes in prolactinoma
ZHOU, W., MA, C., & YAN, Z. (2015) · Neoplasma · doi:10.4149/neo_2015_007 · Cited by 4
“Prolactinoma is the most common type of pituitary tumor as it accounts for 60% of functional pituitary adenomas [1, 2].”
BackgroundThe Pituitary Gland in Pregnancy
Glezer, A., & Bronstein, M. D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804169-7.00013-1 · Cited by 4
Kunasegaran, S., CROXSON, M. S., Holdaway, I. M., & Murphy, R. (2017) · BMJ Case Reports · doi:10.1136/bcr-2017-219921 · Cited by 4
Management of pituitary tumors during pregnancy and lactation
Glezer, A., Jallad, R., Machado, M., Fragoso, M., & Bronstein, M. (2018) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2018.02.002 · Cited by 3
Description of clinical portraits of patients with hyperprolactinemia
Dzeranova, L. K., Fedorova, N. S., Vorotnikova, S. Y., & Pigarova, E. A. (2018) · Obesity and metabolism · doi:10.14341/omet9866 · Cited by 4
Pituitary microadenomas — current diagnostic and treatment methods
Astafyeva, L. I., Кадашев, Б. А., Sidneva, Y., Chernov, I. V., & Kalinin, P. L. (2020) · Burdenko s Journal of Neurosurgery · doi:10.17116/neiro202084021110 · Cited by 8
Prolactin ordering patterns in psychiatric inpatients and the impact this has on patient management
Jones, A. S., Sztal‐Mazer, S., Rauchberger, I., & Hamblin, P. S. (2020) · Australasian Psychiatry · doi:10.1177/1039856220934326 · Cited by 4
Schizophrenia and Macroprolactinoma: Is There a Deep Link?
Bamarinejad, A., Nasiri, S., Bamarinejad, F., Salehidoost, R., & Zare–Farashbandi, E. (2020) · Advanced Biomedical Research · doi:10.4103/abr.abr_96_20 · Cited by 4
“Pituitary tumors contain about 10%–15% of all intracranial tumors.[1] Prolactinomas are the most common type of functional pituitary tumors.”
BackgroundMale Infertility: Evaluation and Treatment
Zubi, Z. B. H., Alfarisi, H. A. H., Wahab, A. A., Fuaat, A. A., Mohamad, C. C., & Ibrahim, M. I. (2020) · IIUM Medical Journal Malaysia · doi:10.31436/imjm.v19i3.1670 · Cited by 5
“In resistant prolactinomas, it is recommended to increase the dose to the maximum tolerated dose before surgical intervention.(22) Infertile men with low serum testosterone to estradiol ratio can be treated with aromatase inhibitors such as testolactone and anstrazole.”
BackgroundErectile dysfunction pattern in patients with end stage renal disease on regular dialysis
Abdelaal, M. A., Abouelgreed, T. A., Ibrahim, A. H., Elshater, A. I., & Sabry, K. M. (2021) · Urologia Journal · doi:10.1177/03915603211007056 · Cited by 5
A case of hyperprolactinaemia in a patient with metastatic melanoma
Manning, A., Rassie, K. L., & Rivalland, G. (2021) · Melanoma Research · doi:10.1097/cmr.0000000000000738 · Cited by 4
Tumor stem-like cells isolated from MMQ cells resist to dopamine agonist treatment
Cai, L., Chen, J., Lu, J., Li, Q., Chen, X., Zhang, L., Wu, J., Zheng, W., Wang, C., & Su, Z. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111396 · Cited by 4
Castro, M. A., Mariño‐Sánchez, F., Fernández, A. G., Cancela, A. A., & Berrocal, V. R. (2021) · Neurocirugía · doi:10.1016/j.neucir.2021.07.004 · Cited by 6
Functional Lactotrophs in Induced Adenohypophysis Differentiated From Human iPS Cells
Miyake, N., Nagai, T., Suga, H., Osuka, S., Kasai, T., Sakakibara, M., Soen, M., Ozaki, H., Miwata, T., Asano, T., et al. (2022) · Endocrinology · doi:10.1210/endocr/bqac004 · Cited by 8
Genetics of Pituitary Adenomas
Bogusławska, A., Gilis‐Januszewska, A., & Korbonits, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-90475-3_4 · Cited by 6
Guo, X., Chen, J., Zhang, Z., Wan, X., Shu, K., & Lei, T. (2022) · Brain Sciences · doi:10.3390/brainsci12060699 · Cited by 4
“Pituitary prolactin-secreting adenomas are the most common functional pituitary adenomas, accounting for approximately 50% of all pituitary adenomas that require treatment [6].”
BackgroundRelationship between prolactin level and puberty in girls with early breast development
Lee, Y. J., & Lee, S. Y. (2022) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2022-0093 · Cited by 4
Niknam, A., Mahboobifard, F., Rahmati, M., Firouzi, F., Rojhani, E., Azizi, F., & Tehrani, F. R. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01225-x · Cited by 5
Paragliola, R. M., Binart, N., & Salvatori, R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99899-4.00025-1 · Cited by 6
Varlamov, E. V., & Fleseriu, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99899-4.00019-6 · Cited by 6
Krysiak, R. G., Kowalcze, K. E., & Okopień, B. (2023) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2245 · Cited by 3
An update on, and genetics of refractory adenomas of childhood
Stratakis, C. A. (2023) · Pituitary · doi:10.1007/s11102-023-01327-2 · Cited by 4
Acosta‐Martínez, M. (2023) · Handbook of experimental pharmacology · doi:10.1007/164_2023_666 · Cited by 6
Liu, H., Zhang, X., Chen, W., Xu, Y., Lin, X., & Lin, A. (2023) · Neurological Sciences · doi:10.1007/s10072-023-07008-z · Cited by 5
Endokrinologie der Schwangerschaft
Tóth, B., & Vomstein, K. (2024) · Springer eBooks · doi:10.1007/978-3-662-65517-7_7 · Cited by 4
Heller, C., Güllmar, D., Koeppel, C. J., Rojczyk, P., Stein, H., Taylor, C. M., Jacobs, E. G., Derntl, B., Kikinis, Z., Walter, M., et al. (2024) · npj Women s Health · doi:10.1038/s44294-024-00023-1 · Cited by 9
“Hyperprolactinemia is the most common pituitary hormone hypersecretion syndrome, which most commonly affects women between the ages of 25 and 34 76 , with women often reporting irregular menstrual cycles 77 .”
The data of national medical interview on hyperprolactinemia treatment in real clinical practice
Mel'nichenko, G. A., Dzeranova, L. K., Pigarova, E. A., Vorotnikova, S. Y., & Tarasova, T. S. (2016) · Obesity and metabolism · doi:10.14341/omet2016214-19 · Cited by 4
Prior, J. C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814823-5.00015-5 · Cited by 4
Hyperprolactinemia syndrome: from theory to practice
Adamyan, L. V., Yarmolinskaya, M. I., & Suslova, E. V. (2020) · Russian Journal of Human Reproduction · doi:10.17116/repro20202602127 · Cited by 4
Introduction to Endocrine Disorders in Pregnancy
Pearce, E. N. (2022) · Springer eBooks · doi:10.1007/978-3-030-84367-0_33 · Cited by 4
Tng, E.-L., Teo, A. E. D., & Aung, A. T. (2023) · Journal of Medical Case Reports · doi:10.1186/s13256-023-03820-5 · Cited by 4
Urine oligosaccharide pattern in patients with hyperprolactinaemia
Ekman, B., Wahlberg, J., & Landberg, E. (2015) · Glycoconjugate Journal · doi:10.1007/s10719-015-9610-x · Cited by 4
Diagnostic Evaluation of the Lesions of the Sellar and Parasellar Region
Attanasio, R., Cozzi, R. C., Lasio, G. B., & Barb, R. (2012) · InTech eBooks · doi:10.5772/31173 · Cited by 4
“Obviously all hypersecreting tumors, whether clinically or incidentally diagnosed, should be appropriately treated with surgery or drugs, according to type of tumor and relative guidelines (Biller et al., 2008; Cozzi et al., 2009a; Melmed et al., 2011).”
BackgroundСовременные подходы к диагностике и лечению гиперпролактинемии
Татарчук, Т. Ф., Gunkov, S. V., & Ефименко, О. А. (2012) · Reproductive Endocrinology · doi:10.18370/2309-4117.2012.3.26-44 · Cited by 4
Lewandowski, K. C., Gąsior‐Perczak, D., Kowalska, A., & Lewiñski, A. (2012) · Thyroid Research · doi:10.1186/1756-6614-5-20 · Cited by 4
Differential diagnosis and management of abnormal uterine bleeding due to hyperprolactinemia
Adra, A. M., Zibdeh, M., Malek, A. M. M. A., Hamrahian, A. H., Abdelhamid, A. M. S., Colao, A., Anastasiades, E., Ahmed, E. M. A. F., EZEDDINE, J., Sattar, M. I. A. E., et al. (2016) · Middle East Fertility Society Journal · doi:10.1016/j.mefs.2016.02.001 · Cited by 5
Concomitant Cushing's Disease and Marked Hyperprolactinemia: Response to a Dopamine Receptor Agonist
Shiraishi, J., Koyama, H., Shirakawa, M., Ishikura, R., Okazaki, H., Kurajoh, M., Shoji, T., Moriwaki, Y., Yamamoto, T., & Namba, M. (2016) · Internal Medicine · doi:10.2169/internalmedicine.55.5301 · Cited by 4
Soh, N. A. A. C., Omar, J., Mohamed, W. M. I. W., Abdullah, M. R., & Yaacob, N. M. (2016) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2016.08.001 · Cited by 4
Hormonanalytik – was der Frauenarzt wissen muss
Segerer, S. E., Sonntag, B., Gutensohn, K., & Keck, C. (2018) · Der Gynäkologe · doi:10.1007/s00129-018-4319-0 · Cited by 4
Prolactinoma and Gestation: A Reality
Naliato, E. C. O., Vanni, G. N. M., Melo, R. P. S., & Violante, A. (2018) · Critical Care Obstetrics and Gynecology · doi:10.21767/2471-9803.1000163 · Cited by 4
Molitch, M. E. (2019) · Contemporary Endocrinology · doi:10.1007/978-3-030-11836-5_9 · Cited by 4
Najafabadi, A. H. Z., Zandbergen, I. M., de Vries, F., Broersen, L. H. A., Marle, M. E. V. D. A., Pereira, A. M., Peul, W. C., Dekkers, O. M., van Furth, W. R., & Biermasz, N. R. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa333 · Cited by 4
Alshabeeb, Z. H., Alsuwayni, B. M., Alshargi, O., & Abdelazeem, A. H. (2024) · Current Drug Safety · doi:10.2174/0115748863280407240305070905 · Cited by 3
Ma, K., Ma, L., Huang, T., Wang, Y., Zhong, G., Gao, C., Zhou, Z., & Luo, J. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2416918 · Cited by 5
A Narrative Review of Surgery for Prolactinomas: Considerations and Controversies
Mann, J. A., Starreveld, Y. P., Riva-Cambrin, J. K., & Lithgow, K. C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041089 · Cited by 3
“At presentation, they are classified based on maximum dimensions: macroprolacti-nomas are >1 cm and microprolactinomas are 1 cm [2].”
InfluentialNolan, B. J., Accatino, M. I., Angus, L. M., & Cheung, A. S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1608108 · Cited by 4
Mele, C., Zavattaro, M., Pitino, R., Romanisio, M., Ferrero, A., Sturnia, S., Catenazzi, S., Rosmini, F., Baldi, S., Marzullo, P., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1664621 · Cited by 3
Mortality in patients with dopamine agonist-treated hyperprolactinemia: a large matched-cohort study
Ayalon‐Dangur, I., Shimon, I., Shochat, T., Kushnir, S., Rudman, Y., Dotan, I., Agrawal, N., Fleseriu, M., & Akirov, A. (2025) · Pituitary · doi:10.1007/s11102-025-01594-1 · Cited by 3
“Neither the Endocrine Society’s clinical practice guideline nor the recent international consensus statement by the Pituitary Society specifically address the issue of mortality risk [2, 16].”
Pituitary hormone deficiencies in prolactinomas: prevalence, predictors, and functional recovery
Prinzi, A., Fava, G., Bacchi, I., Federica, S., Galvano, A., Arnaldi, G., Frasca, F., Guarnotta, V., & Malandrino, P. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1705300 · Cited by 4
Approach to the Patient With Dopamine-Resistant Microprolactinoma
Glezer, A., Stumpf, M. A. M., & Queiroz, N. L. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf624 · Cited by 5
Galactorrhea and Pituitary Microadenoma in an 18-Year-Old Transfeminine Youth: A Case Report
Bongsebandhu‐phubhakdi, C., Jakchairoongruang, K., & Poonmaksatit, S. (2025) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2025.12.006 · Cited by 3
“10,11 While microadenomas are small, they may still exert pressure or disrupt hormonal balance, leading to persistent headaches.”
Matos, T., Dias, D., Silvestre, C., Serra, F. A., Araujo-Castro, M., Biagetti, B., Sagarribay, A., Sapinho, I., & Marques, P. (2026) · Pituitary · doi:10.1007/s11102-025-01627-9 · Cited by 3
Gadelha, M. R., Wildemberg, L. E., & Kasuki, L. (2022) · The Pituitary · doi:10.1016/b978-0-323-99899-4.00003-2 · Cited by 2
Metadata
- Authors
- Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J. A., & Wass, J. A. H.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Universidade de Santiago de Compostela (ES)
- VA Palo Alto Health Care System (US)
- New York University (US)
- University of Iowa (US)
- Churchill Hospital (GB)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-02
- Volume
- 96
- Issue
- 2
- Pages
- 273-288
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2019055295
- Semantic Scholar
- 43454263bc46394124a75b19ce2b73452ff5e993
- Cited by
- 1,844
- References
- 141
- Citations by year
- 2026: 133 · 2025: 125 · 2024: 141 · 2023: 150 · 2022: 186 · 2021: 170 · 2020: 138 · 2019: 148 · 2018: 103 · 2017: 107 · 2016: 102 · 2015: 97 · 2014: 76 · 2013: 66 · 2012: 71
- FWCI
- 61.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, other-oa)
- Funders
- U.S. Department of Defense
- Eli Lilly and Company
- Pfizer
- Teva Pharmaceutical Industries
- European Society of Endocrinology
- Novo Nordisk
- Ipsen
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- hyperprolactinemia, prolactinoma, drug-induced hyperprolactinemia, prolactinoma treatment, pregnancy
- MeSH terms
- Adult, Female, Humans, Hyperprolactinemia, Pituitary Neoplasms, Pregnancy, Prolactinoma, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.